# Henry J Duff

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 115 papers | 4,756 citations | 38 h-index | 66 g-index |
| 119 ext. papers | 5,384 ext. citations | 7.2 avg, IF | 4.9 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 115 | D. George Wyse, MD, PhD, FRCPC, FHRS (1941-2022).. *Heart Rhythm*, **2022**, 19, 513-514 | 6.7 | |
| 114 | Lipid regulation of hERG1 channel function. *Nature Communications*, **2021**, 12, 1409 | 17.4 | 2 |
| 113 | Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry. *European Heart Journal*, **2021**, 42, 2827-2838 | 8.5 | 18 |
| 112 | Refinement of a cryo-EM structure of hERG: Bridging structure and function. *Biophysical Journal*, **2021**, 120, 738-748 | 2.9 | 2 |
| 111 | Toward Reducing hERG Affinities for DAT Inhibitors with a Combined Machine Learning and Molecular Modeling Approach. *Journal of Chemical Information and Modeling*, **2021**, 61, 4266-4279 | 6.1 | 4 |
| 110 | An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. *Circulation*, **2020**, 141, 429-439 | 16.7 | 15 |
| 109 | Selectivity filter modalities and rapid inactivation of the hERG1 channel. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 2795-2804 | 11.5 | 17 |
| 108 | Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. *Canadian Journal of Cardiology*, **2020**, 36, 543-553 | 3.8 | 40 |
| 107 | Allosteric Coupling Between Drug Binding and the Aromatic Cassette in the Pore Domain of the hERG1 Channel: Implications for a State-Dependent Blockade. *Frontiers in Pharmacology*, **2020**, 11, 914 | 5.6 | 4 |
| 106 | Characterization of a Unique Form of Arrhythmic Cardiomyopathy Caused by Recessive Mutation in LEMD2. *JACC Basic To Translational Science*, **2019**, 4, 204-221 | 8.7 | 14 |
| 105 | A computational model of induced pluripotent stem-cell derived cardiomyocytes incorporating experimental variability from multiple data sources. *Journal of Physiology*, **2019**, 597, 4533-4564 | 3.9 | 38 |
| 104 | The Pore-Lipid Interface: Role of Amino-Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain. *Molecular Pharmacology*, **2019**, 96, 259-271 | 4.3 | 15 |
| 103 | Macrophage Uptake of Necrotic Cell DNA Activates the AIM2 Inflammasome to Regulate a Proinflammatory Phenotype in CKD. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 1165-1181 | 12.7 | 61 |
| 102 | Determinants of Isoform-Specific Gating Kinetics of hERG1 Channel: Combined Experimental and Simulation Study. *Frontiers in Physiology*, **2018**, 9, 207 | 4.6 | 17 |
| 101 | Genetic Determinants of Hereditary Bradyarrhythmias: A Contemporary Review of a Diverse Group of Disorders. *Canadian Journal of Cardiology*, **2017**, 33, 758-767 | 3.8 | 9 |
| 100 | Suppression of ryanodine receptor function prolongs Ca2+ release refractoriness and promotes cardiac alternans in intact hearts. *Biochemical Journal*, **2016**, 473, 3951-3964 | 3.8 | 20 |
| 99 | Role of the pH in state-dependent blockade of hERG currents. *Scientific Reports*, **2016**, 6, 32536 | 4.9 | 20 |

| | | | |
|---|---|---|---|
| 98 | Reversible Dilated Cardiomyopathy Caused by a High Burden of Ventricular Arrhythmias in Andersen-Tawil Syndrome. *Canadian Journal of Cardiology*, **2016**, 32, 1576.e15-1576.e18 | 3.8 | 2 |
| 97 | Role of mutation and pharmacologic block of human KCNH2 in vasculogenesis and fetal mortality: partial rescue by transforming growth factor- *Circulation: Arrhythmia and Electrophysiology*, **2015**, 8, 420-8 | 6.4 | 7 |
| 96 | NS1643 interacts around L529 of hERG to alter voltage sensor movement on the path to activation. *Biophysical Journal*, **2015**, 108, 1400-1413 | 2.9 | 23 |
| 95 | Kinetic model for NS1643 drug activation of WT and L529I variants of Kv11.1 (hERG1) potassium channel. *Biophysical Journal*, **2015**, 108, 1414-1424 | 2.9 | 18 |
| 94 | In response to Melgari et al. "hERG potassium channel inhibition by ivabradine requires channel gating". *Journal of Molecular and Cellular Cardiology*, **2015**, 87, 192-3 | 5.8 | |
| 93 | Hierarchical regulation of wound healing by NOD-like receptors in cardiovascular disease. *Antioxidants and Redox Signaling*, **2015**, 22, 1176-87 | 8.4 | 15 |
| 92 | Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4. *Journal of Molecular and Cellular Cardiology*, **2015**, 85, 71-8 | 5.8 | 46 |
| 91 | The ryanodine receptor store-sensing gate controls Ca2+ waves and Ca2+-triggered arrhythmias. *Nature Medicine*, **2014**, 20, 184-92 | 50.5 | 135 |
| 90 | Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity. *BMC Pharmacology & Toxicology*, **2014**, 15, 14 | 2.6 | 14 |
| 89 | Structure driven design of novel human ether-a-go-go-related-gene channel (hERG1) activators. *PLoS ONE*, **2014**, 9, e105553 | 3.7 | 14 |
| 88 | Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome. *Journal of Biological Chemistry*, **2014**, 289, 19571-84 | 5.4 | 99 |
| 87 | Inflammasome-independent NLRP3 augments TGF- signaling in kidney epithelium. *Journal of Immunology*, **2013**, 190, 1239-49 | 5.3 | 162 |
| 86 | The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1 *Experimental Physiology*, **2013**, 98, 462-72 | 2.4 | 123 |
| 85 | Phospholamban knockout breaks arrhythmogenic Ca+ waves and suppresses catecholaminergic polymorphic ventricular tachycardia in mice. *Circulation Research*, **2013**, 113, 517-26 | 15.7 | 52 |
| 84 | Auto-entrainment risk assessment in heart failure. *Circulation: Arrhythmia and Electrophysiology*, **2013**, 6, 129-36 | 6.4 | 1 |
| 83 | Structure-guided topographic mapping and mutagenesis to elucidate binding sites for the human ether-a-go-go-related gene 1 potassium channel (KCNH2) activator NS1643. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 342, 441-52 | 4.7 | 25 |
| 82 | Modeling of open, closed, and open-inactivated states of the hERG1 channel: structural mechanisms of the state-dependent drug binding. *Journal of Chemical Information and Modeling*, **2012**, 52, 2760-74 | 6.1 | 60 |
| 81 | Cell therapy limits myofibroblast differentiation and structural cardiac remodeling: basic fibroblast growth factor-mediated paracrine mechanism. *Circulation: Heart Failure*, **2012**, 5, 349-56 | 7.6 | 27 |

| | | | |
|---|---|---|---|
| 80 | Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain. *Journal of Chemical Information and Modeling*, **2011**, 51, 463-74 | 6.1 | 77 |
| 79 | Impact of stirred suspension bioreactor culture on the differentiation of murine embryonic stem cells into cardiomyocytes. *BMC Cell Biology*, **2011**, 12, 53 | | 22 |
| 78 | Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. *Nature Medicine*, **2011**, 17, 1003-9 | 50.5 | 157 |
| 77 | Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane and molecular dynamics simulations. *Proteins: Structure, Function and Bioinformatics*, **2010**, 78, 2922-34 | 4.2 | 44 |
| 76 | Impact of atrial antitachycardia pacing and atrial pace prevention therapies on atrial fibrillation burden over long-term follow-up. *Europace*, **2009**, 11, 1041-7 | 3.9 | 13 |
| 75 | Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. *Nature Medicine*, **2009**, 15, 380-3 | 50.5 | 436 |
| 74 | Interactions of H562 in the S5 helix with T618 and S621 in the pore helix are important determinants of hERG1 potassium channel structure and function. *Biophysical Journal*, **2009**, 96, 3600-10 | 2.9 | 35 |
| 73 | Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. *Heart Rhythm*, **2009**, 6, 984-92 | 6.7 | 158 |
| 72 | Role of magnetic resonance imaging in arrhythmogenic right ventricular dysplasia: insights from the North American arrhythmogenic right ventricular dysplasia (ARVD/C) study. *American Heart Journal*, **2008**, 155, 147-53 | 4.9 | 94 |
| 71 | Polymorphisms in multiple genes are associated with resting heart rate in a stepwise allele-dependent manner. *Heart Rhythm*, **2008**, 5, 694-700 | 6.7 | 10 |
| 70 | hERG: the long and short of it. *Heart Rhythm*, **2008**, 5, 591-2 | 6.7 | 1 |
| 69 | Caffeine induces Ca2+ release by reducing the threshold for luminal Ca2+ activation of the ryanodine receptor. *Biochemical Journal*, **2008**, 414, 441-52 | 3.8 | 116 |
| 68 | Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation. *European Heart Journal*, **2008**, 29, 1873-80 | 9.5 | 21 |
| 67 | iNOS in cardiac myocytes plays a critical role in death in a murine model of hypertrophy induced by calcineurin. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 295, H1122-H1131 | 5.2 | 11 |
| 66 | Homozygous missense N629D hERG (KCNH2) potassium channel mutation causes developmental defects in the right ventricle and its outflow tract and embryonic lethality. *Circulation Research*, **2008**, 103, 1483-91 | 15.7 | 42 |
| 65 | Transmural temporospatial left ventricular activation during pacing from different sites: potential implications for optimal pacing. *Cardiovascular Research*, **2008**, 77, 81-8 | 9.9 | 8 |
| 64 | Skeletal and cardiac ryanodine receptors exhibit different responses to Ca2+ overload and luminal ca2+. *Biophysical Journal*, **2007**, 92, 2757-70 | 2.9 | 29 |
| 63 | Noninvasive risk assessment early after a myocardial infarction the REFINE study. *Journal of the American College of Cardiology*, **2007**, 50, 2275-84 | 15.1 | 261 |

| | | | |
|---|---|---|---|
| 62 | Removal of FKBP12.6 does not alter the conductance and activation of the cardiac ryanodine receptor or the susceptibility to stress-induced ventricular arrhythmias. *Journal of Biological Chemistry*, **2007**, 282, 34828-38 | 5.4 | 77 |
| 61 | Mechanism of hypotensive transients associated with abrupt bradycardias in conscious rabbits. *Canadian Journal of Cardiology*, **2007**, 23, 721-6 | 3.8 | 7 |
| 60 | Calmodulin kinase II accelerates L-type Ca2+ current recovery from inactivation and compensates for the direct inhibitory effect of [Ca2+]i in rat ventricular myocytes. *Journal of Physiology*, **2006**, 574, 509-18 | 3.9 | 31 |
| 59 | Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C. *Heart Rhythm*, **2005**, 2, 860-6 | 6.7 | 44 |
| 58 | Blockade of HERG cardiac K+ current by antifungal drug miconazole. *British Journal of Pharmacology*, **2005**, 144, 840-8 | 8.6 | 34 |
| 57 | Prolonged repolarization and triggered activity induced by adenoviral expression of HERG N629D in cardiomyocytes derived from stem cells. *Cardiovascular Research*, **2004**, 61, 268-77 | 9.9 | 7 |
| 56 | Heart block in mice overexpressing calcineurin but not NF-AT3. *Cardiovascular Research*, **2004**, 64, 488-95 | 9.9 | 11 |
| 55 | In vivo temporal and spatial distribution of depolarization and repolarization and the illusive murine T wave. *Journal of Physiology*, **2004**, 555, 267-79 | 3.9 | 65 |
| 54 | Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ channels. *Cardiovascular Research*, **2003**, 57, 320-32 | 9.9 | 47 |
| 53 | [K(+)](o)-dependent change in conformation of the HERG1 long QT mutation N629D channel results in partial reversal of the in vitro disease phenotype. *Cardiovascular Research*, **2003**, 57, 642-50 | 9.9 | 7 |
| 52 | Clinical and electrophysiologic predictors of ventricular tachyarrhythmia recurrence in patients with implantable cardioverter defibrillators. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 492-8 | 2.7 | 18 |
| 51 | Randomized controlled trial of fixed rate versus rate responsive pacing after radiofrequency atrioventricular junction ablation: quality of life, ventricular refractoriness, and paced QT dispersion. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 1163-70 | 2.7 | 13 |
| 50 | Paced QT dispersion and QT morphology after radiofrequency atrioventricular junction ablation: impact of left ventricular function. *PACE - Pacing and Clinical Electrophysiology*, **2003**, 26, 662-8 | 1.6 | 2 |
| 49 | Selective knockout of mouse ERG1 B potassium channel eliminates I(Kr) in adult ventricular myocytes and elicits episodes of abrupt sinus bradycardia. *Molecular and Cellular Biology*, **2003**, 23, 1856-62 | 4.8 | 49 |
| 48 | Induction of heart rate and blood pressure turbulence in the electrophysiologic laboratory. *American Journal of Cardiology*, **2002**, 90, 1098-102 | 3 | 25 |
| 47 | Effect of stimulation rate, sarcomere length and Ca(2+) on force generation by mouse cardiac muscle. *Journal of Physiology*, **2002**, 544, 817-30 | 3.9 | 56 |
| 46 | Precordial QT dispersion does not predict inducibility of ventricular tachyarrhythmias at post-revascularization electrophysiologic study. *Journal of Interventional Cardiac Electrophysiology*, **2002**, 6, 25-33 | 2.4 | 2 |
| 45 | Conduction time oscillations precede the spontaneous termination of human atrioventricular reciprocating tachycardia. *Journal of Interventional Cardiac Electrophysiology*, **2000**, 4, 231-9 | 2.4 | |

| | | | |
|---|---|---|---|
| 44 | Age-dependent response of the electrocardiogram to K(+) channel blockers in mice. *American Journal of Physiology - Cell Physiology*, **2000**, 278, C73-80 | 5.4 | 40 |
| 43 | Novel gain-of-function mechanism in K(+) channel-related long-QT syndrome: altered gating and selectivity in the HERG1 N629D mutant. *Circulation Research*, **2000**, 86, 507-13 | 15.7 | 65 |
| 42 | Glucocorticoid regulation of cardiac K+ currents and L-type Ca2+ current in neonatal mice. *Circulation Research*, **1999**, 85, 168-73 | 15.7 | 39 |
| 41 | Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. *Journal of the American College of Cardiology*, **1999**, 34, 325-33 | 15.1 | 93 |
| 40 | Prolonged sinus node recovery time in humans after the intracoronary administration of a nitric oxide synthase inhibitor. *Journal of Cardiovascular Pharmacology*, **1999**, 34, 1-6 | 3.1 | 4 |
| 39 | Telemetry-documented, pace-terminable ventricular tachycardia in patients with ventricular fibrillation. *American Journal of Cardiology*, **1998**, 81, 235-8 | 3 | 5 |
| 38 | Antiarrhythmic drug effects on QT interval dispersion in patients undergoing electropharmacologic testing for ventricular tachycardia and fibrillation. *American Journal of Cardiology*, **1998**, 81, 588-93 | 3 | 16 |
| 37 | [3H]dofetilide binding to cardiac myocytes: modulation by extracellular potassium. *Journal of Molecular and Cellular Cardiology*, **1997**, 29, 183-91 | 5.8 | 11 |
| 36 | Regulation of expression of the [3H]-dofetilide binding site associated with the delayed rectifier K+ channel by dexamethasone in neonatal mouse ventricle. *Journal of Molecular and Cellular Cardiology*, **1997**, 29, 1959-65 | 5.8 | 6 |
| 35 | Definition of predicted effective antiarrhythmic drug therapy for ventricular tachyarrhythmias by the electrophysiologic study approach: randomized comparison of patient response criteria. *Journal of the American College of Cardiology*, **1997**, 30, 1346-53 | 15.1 | 17 |
| 34 | Effect of coronary angioplasty on precordial QT dispersion. *American Journal of Cardiology*, **1997**, 79, 1339-42 | 3 | 58 |
| 33 | Developmental changes in transient outward current in mouse ventricle. *Circulation Research*, **1997**, 81, 120-7 | 15.7 | 83 |
| 32 | Electrophysiological characterization of an alternatively processed ERG K+ channel in mouse and human hearts. *Circulation Research*, **1997**, 81, 719-26 | 15.7 | 151 |
| 31 | Hypomagnesemia: characterization of a model of sudden cardiac death. *Journal of the American College of Cardiology*, **1996**, 27, 1771-6 | 15.1 | 30 |
| 30 | Increased precordial QTc dispersion predicts ventricular fibrillation during acute myocardial infarction. *American Journal of Cardiology*, **1996**, 78, 706-8 | 3 | 52 |
| 29 | A randomized clinical trial of the noninvasive and invasive approaches to drug therapy for ventricular tachycardia: long-term follow-up of the Calgary trial. *Progress in Cardiovascular Diseases*, **1996**, 38, 377-84 | 8.5 | 12 |
| 28 | Developmental changes in the delayed rectifier K+ channels in mouse heart. *Circulation Research*, **1996**, 79, 79-85 | 15.7 | 153 |
| 27 | Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. *American Heart Journal*, **1995**, 130, 71-9 | 4.9 | 19 |

| | | | |
|---|---|---|---|
| 26 | Quinidine pharmacodynamics in patients with arrhythmia: effects of left ventricular function. *Journal of the American College of Cardiology*, **1995**, 25, 989-94 | 15.1 | 3 |
| 25 | Long-term reproducibility of ventricular tachycardia induction in patients with implantable cardioverter/defibrillators. Serial noninvasive studies. *Circulation*, **1995**, 91, 2605-13 | 16.7 | 10 |
| 24 | Biochemical and biophysical studies of the interaction of class I antiarrhythmic drugs with the cardiac sodium channel. *Drug Development Research*, **1994**, 33, 277-294 | 5.1 | 2 |
| 23 | Risks of developing supraventricular and ventricular tachyarrhythmias after implantation of a cardioverter-defibrillator, and timing the activation of arrhythmia termination therapies. *American Journal of Cardiology*, **1993**, 71, 565-8 | 3 | 10 |
| 22 | Comparison of biphasic and monophasic shocks for defibrillation using a nonthoracotomy system. *American Journal of Cardiology*, **1993**, 71, 197-202 | 3 | 81 |
| 21 | Characteristics of patients with nonfatal cardiac arrest 3 to 180 days after acute myocardial infarction. *American Journal of Cardiology*, **1993**, 72, 753-8 | 3 | 5 |
| 20 | Use-dependent electrophysiologic effects of amiodarone in coronary artery disease and inducible ventricular tachycardia. *American Journal of Cardiology*, **1992**, 70, 598-604 | 3 | 1 |
| 19 | Effects of left ventricular dysfunction on the circadian variation of ventricular premature complexes in healed myocardial infarction. *American Journal of Cardiology*, **1992**, 69, 1009-14 | 3 | 26 |
| 18 | Comparison of atrial overdrive pacing with and without extrastimuli for termination of atrial flutter. *American Journal of Cardiology*, **1992**, 70, 463-7 | 3 | 26 |
| 17 | Drug therapy for ventricular tachyarrhythmias: how many electropharmacologic trials are appropriate?. *Journal of the American College of Cardiology*, **1991**, 17, 391-6 | 15.1 | 26 |
| 16 | Reduction in defibrillator shocks with an implantable device combining antitachycardia pacing and shock therapy. *Journal of the American College of Cardiology*, **1991**, 18, 145-51 | 15.1 | 109 |
| 15 | Clinical pharmacokinetics of propafenone. *Clinical Pharmacokinetics*, **1991**, 21, 1-10 | 6.2 | 40 |
| 14 | Transcainide: biochemical evidence for state-dependent interaction with the class I antiarrhythmic drug receptor. *European Journal of Pharmacology*, **1991**, 203, 51-8 | 5.3 | 1 |
| 13 | Drug response at electropharmacologic study in patients with ventricular tachyarrhythmias: the importance of ventricular refractoriness. *Journal of the American College of Cardiology*, **1991**, 17, 914-20 | 15.1 | 22 |
| 12 | Contribution of quinidine metabolites to electrophysiologic responses in human subjects. *Clinical Pharmacology and Therapeutics*, **1989**, 46, 352-8 | 6.1 | 13 |
| 11 | Concentration-response relationships of disopyramide in patients with ventricular tachycardia. *Clinical Pharmacology and Therapeutics*, **1989**, 45, 542-7 | 6.1 | 7 |
| 10 | Hemodialysis removal of propafenone. *Pharmacotherapy*, **1989**, 9, 331-3 | 5.8 | 9 |
| 9 | Propafenone disposition in renal insufficiency and renal failure. *Journal of Clinical Pharmacology*, **1989**, 29, 112-3 | 2.9 | 12 |

| | | | |
|---|---|---|---|
| 8 | Effect of oral combination therapy with mexiletine and quinidine on left and right ventricular function. *American Heart Journal*, **1988**, 115, 1030-6 | 4.9 | 11 |
| 7 | A randomized clinical trial of the noninvasive and invasive approaches to drug therapy of ventricular tachycardia. *New England Journal of Medicine*, **1987**, 317, 1681-7 | 59.2 | 169 |
| 6 | Programmed electrical stimulation studies for ventricular tachycardia induction in humans. I. The role of ventricular functional refractoriness in tachycardia induction. *Journal of the American College of Cardiology*, **1986**, 8, 567-75 | 15.1 | 65 |
| 5 | Programmed electrical stimulation studies for ventricular tachycardia induction in humans. II. Comparison of indwelling electrode catheter and daily catheter replacement. *Journal of the American College of Cardiology*, **1986**, 8, 576-81 | 15.1 | 25 |
| 4 | Intravenous quinidine: relations among concentration, tachyarrhythmia suppression and electrophysiologic actions with inducible sustained ventricular tachycardia. *American Journal of Cardiology*, **1985**, 55, 92-7 | 3 | 17 |
| 3 | Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency. *American Journal of Cardiology*, **1982**, 50, 305-12 | 3 | 24 |
| 2 | Control of ventricular preexcitation and associated arrhythmias by encainide. *American Heart Journal*, **1981**, 102, 794-7 | 4.9 | 10 |
| 1 | Detection of entrapped intracardiac air with intraoperative echocardiography. *American Journal of Cardiology*, **1980**, 46, 255-60 | 3 | 28 |